

# Claudio Gasperini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4291428/publications.pdf>

Version: 2024-02-01

121  
papers

6,144  
citations

81743

39  
h-index

79541

73  
g-index

123  
all docs

123  
docs citations

123  
times ranked

6795  
citing authors

#	ARTICLE	IF	CITATIONS
1	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , 2022, 269, 933-944.	1.8	10
2	mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 448-450.	0.9	53
3	Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies. <i>Journal of Neurology</i> , 2022, 269, 1114-1120.	1.8	23
4	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsingâ€“remitting multiple sclerosis patients. <i>Journal of Neurology</i> , 2022, 269, 452-459.	1.8	10
5	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome. <i>Neurology</i> , 2022, 98, .	1.5	31
6	Humoral- and T-Cellâ€“Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies. <i>Neurology</i> , 2022, 98, .	1.5	125
7	Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies. <i>Journal of Neurology</i> , 2022, 269, 2275-2285.	1.8	18
8	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6â€“years. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2137-2141.	1.4	3
9	A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 499-511.	1.4	5
10	Shift of multiple sclerosis onset towards older age. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 1137-1139.	0.9	12
11	Efficacy of prolonged-release fampridine <i>versus</i> placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642210903.	1.5	1
12	Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1391-1402.	1.4	27
13	The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease. <i>Multiple Sclerosis Journal</i> , 2021, 27, 968-972.	1.4	3
14	Unilateral meningitis: unusual central nervous system involvement in rheumatoid arthritis. <i>Practical Neurology</i> , 2021, 21, 167-168.	0.5	2
15	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. <i>European Journal of Neurology</i> , 2021, 28, 1299-1307.	1.7	12
16	The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis. <i>Journal of Clinical Psychology in Medical Settings</i> , 2021, 28, 149-160.	0.8	17
17	Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110112.	1.5	0
18	Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study. <i>NeuroImage: Clinical</i> , 2021, 29, 102549.	1.4	20

#	ARTICLE	IF	CITATIONS
19	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110195.	1.5	48
20	Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references. <i>NeuroImage: Clinical</i> , 2021, 30, 102659.	1.4	3
21	Tailored Vessel-Catheter Diameter Ratio in a Direct Aspiration First-Pass Technique: Is It a Matter of Caliber?. <i>American Journal of Neuroradiology</i> , 2021, 42, 546-550.	1.2	6
22	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 780-789.	2.8	370
23	Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter compartmentalization. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 623-630.	1.7	14
24	Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. <i>Journal of Neurology</i> , 2021, 268, 2922-2932.	1.8	18
25	Ozone-induced encephalopathy: A novel iatrogenic entity. <i>European Journal of Neurology</i> , 2021, 28, 2471-2478.	1.7	2
26	Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score. <i>European Journal of Neurology</i> , 2021, 28, 2533-2542.	1.7	16
27	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. <i>Journal of Neurology</i> , 2021, 268, 3961-3968.	1.8	47
28	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	1.7	86
29	Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	27
30	2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. <i>Lancet Neurology</i> , The, 2021, 20, 653-670.	4.9	302
31	Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support. <i>Disability and Rehabilitation</i> , 2020, 42, 3780-3792.	0.9	17
32	Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study. <i>Journal of Neurology</i> , 2020, 267, 694-702.	1.8	6
33	Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled Trial. <i>Neurotherapeutics</i> , 2020, 17, 704-709.	2.1	5
34	EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e876.	3.1	6
35	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirms group. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102394.	0.9	2
36	Mapping the Progressive Treatment-Related Reduction of Active MRI Lesions in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 585296.	1.1	4

#	ARTICLE	IF	CITATIONS
37	Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study. <i>Neurotherapeutics</i> , 2020, 17, 994-1004.	2.1	34
38	Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort. <i>Journal of Neurology</i> , 2020, 267, 3541-3554.	1.8	14
39	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. <i>Nature Reviews Neurology</i> , 2020, 16, 171-182.	4.9	150
40	Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 388-391.	0.9	14
41	Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 271-277.	0.9	29
42	Longitudinal Assessment of Multiple Sclerosis with the Brainâ€Age Paradigm. <i>Annals of Neurology</i> , 2020, 88, 93-105.	2.8	79
43	Effect of dalfampridine on information processing speed impairment in multiple sclerosis. <i>Neurology</i> , 2019, 93, e733-e746.	1.5	21
44	Lifespan normative data on rates of brain volume changes. <i>Neurobiology of Aging</i> , 2019, 81, 30-37.	1.5	40
45	CD28 Autonomous Signaling Up-Regulates C-Myc Expression and Promotes Glycolysis Enabling Inflammatory T Cell Responses in Multiple Sclerosis. <i>Cells</i> , 2019, 8, 575.	1.8	30
46	Distinct Expression of Inflammatory Features in T Helper 17 Cells from Multiple Sclerosis Patients. <i>Cells</i> , 2019, 8, 533.	1.8	14
47	Resiquimod-Mediated Activation of Plasmacytoid Dendritic Cells Is Amplified in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2811.	1.8	3
48	â€œBetter explanationsâ€ in multiple sclerosis diagnostic workup. <i>Neurology</i> , 2019, 92, e2527-e2537.	1.5	44
49	How much do periventricular lesions assist in distinguishing migraine with aura from CIS?. <i>Neurology</i> , 2019, 92, e1739-e1744.	1.5	15
50	Unraveling treatment response in multiple sclerosis. <i>Neurology</i> , 2019, 92, 180-192.	1.5	88
51	Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 352-360.	1.4	22
52	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. <i>Nature Reviews Neurology</i> , 2018, 14, 199-213.	4.9	157
53	FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis. <i>Scientific Reports</i> , 2018, 8, 3674.	1.6	42
54	Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients: implication in peripheral inflammation. <i>Scientific Reports</i> , 2018, 8, 1319.	1.6	41

#	ARTICLE	IF	CITATIONS
55	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. <i>Lancet Neurology</i> , The, 2018, 17, 133-142.	4.9	98
56	Deep gray matter volume loss drives disability worsening in multiple sclerosis. <i>Annals of Neurology</i> , 2018, 83, 210-222.	2.8	295
57	A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study. <i>Journal of Neurology</i> , 2018, 265, 1174-1183.	1.8	23
58	Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report. <i>Journal of Neurology</i> , 2018, 265, 2152-2153.	1.8	7
59	Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectives. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2018, 3, .	1.1	20
60	Fingolimod vs dimethyl fumarate in multiple sclerosis. <i>Neurology</i> , 2018, 91, e153-e161.	1.5	35
61	Three-Tesla MRI does not improve the diagnosis of multiple sclerosis. <i>Neurology</i> , 2018, 91, e249-e257.	1.5	26
62	Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 1081-1089.	1.4	20
63	Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy. <i>Neuroepidemiology</i> , 2017, 48, 171-178.	1.1	6
64	Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis. <i>Molecular Neurobiology</i> , 2017, 54, 7520-7533.	1.9	47
65	Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis. <i>Journal of Neurology</i> , 2017, 264, 284-294.	1.8	44
66	Dysregulated Homeostasis of Acetylcholine Levels in Immune Cells of RR-Multiple Sclerosis Patients. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2009.	1.8	25
67	Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29. <i>Journal of the Neurological Sciences</i> , 2016, 370, 123-131.	0.3	11
68	Assessing response to interferon- $\beta$ in a multicenter dataset of patients with MS. <i>Neurology</i> , 2016, 87, 134-140.	1.5	98
69	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. <i>Lancet Neurology</i> , The, 2016, 15, 292-303.	4.9	679
70	Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial. <i>Multiple Sclerosis Journal</i> , 2016, 22, 212-221.	1.4	56
71	Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems. <i>Journal of Neurology</i> , 2016, 263, 751-759.	1.8	35
72	Visual pathway neurodegeneration winged by mitochondrial dysfunction. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 140-150.	1.7	13

#	ARTICLE	IF	CITATIONS
73	T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis. <i>Clinical Science</i> , 2015, 129, 291-303.	1.8	55
74	The p38 mitogen-activated protein kinase cascade modulates T helper type 17 differentiation and functionality in multiple sclerosis. <i>Immunology</i> , 2015, 146, 251-263.	2.0	24
75	Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1713-1722.	1.4	23
76	Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing&ndash;remitting multiple sclerosis. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 229.	0.9	43
77	Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1265-1268.	1.4	17
78	From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study. <i>European Neurology</i> , 2014, 71, 233-241.	0.6	4
79	CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes. <i>Immunology Letters</i> , 2014, 158, 134-142.	1.1	36
80	Serum lactate as a novel potential biomarker in multiple sclerosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1137-1143.	1.8	77
81	Effects of Bacille Calmette-Guérin after the first demyelinating event in the CNS. <i>Neurology</i> , 2014, 82, 41-48.	1.5	128
82	MxA mRNA Quantification and Disability Progression in Interferon Beta-Treated Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2014, 9, e94794.	1.1	14
83	Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1243-1253.	1.9	10
84	Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. <i>Neurology</i> , 2013, 80, 234-241.	1.5	53
85	A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. <i>Neurological Sciences</i> , 2013, 34, 197-203.	0.9	3
86	Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. <i>Neurology</i> , 2013, 80, 2090-2094.	1.5	63
87	Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis. <i>PLoS Pathogens</i> , 2013, 9, e1003220.	2.1	132
88	Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. <i>Annals of Neurology</i> , 2013, 73, 626-636.	2.8	83
89	Efficacy and safety of laquinimod in multiple sclerosis: current status. <i>Therapeutic Advances in Neurological Disorders</i> , 2013, 6, 343-352.	1.5	18
90	Advances in the treatment of relapsing&ndash;remitting multiple sclerosis &ndash; critical appraisal of fingolimod. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 73.	0.9	15

#	ARTICLE	IF	CITATIONS
91	Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 64-71.	1.4	85
92	Efficacy and safety of subcutaneous interferon beta-1a in relapsing&#x2013;remitting multiple sclerosis: Further outcomes from the IMPROVE study. <i>Journal of the Neurological Sciences</i> , 2012, 312, 97-101.	0.3	31
93	Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach. <i>Drug Design, Development and Therapy</i> , 2012, 6, 175.	2.0	38
94	Emerging oral drugs for relapsing&#x2013;remitting multiple sclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 697-712.	1.0	13
95	Impaired cortical deactivation during hand movement in the relapsing phase of multiple sclerosis: a cross-sectional and longitudinal fMRI study. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1177-1184.	1.4	10
96	Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis. <i>PLoS ONE</i> , 2011, 6, e19452.	1.1	74
97	T Regulatory Cells Are Markers of Disease Activity in Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2011, 6, e21386.	1.1	64
98	Emerging oral treatments in multiple sclerosis &#x2013; clinical utility of cladribine tablets. <i>Therapeutics and Clinical Risk Management</i> , 2010, 6, 391.	0.9	6
99	The prevalence of multiple sclerosis in central Italy. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1432-1436.	1.4	22
100	Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing&#x2013;remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 888-892.	1.4	31
101	Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study. <i>BMC Neurology</i> , 2009, 9, 54.	0.8	25
102	New oral drugs for multiple sclerosis. <i>Neurological Sciences</i> , 2009, 30, 179-183.	0.9	49
103	Emerging oral drugs for multiple sclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 465-477.	1.0	17
104	Safety and Tolerability in Relapsing-Remitting Multiple Sclerosis Patients Treated With High-Dose Subcutaneous Interferon-Beta by Rebiject Autoinjection Over a 1-Year Period. <i>Clinical Neuropharmacology</i> , 2008, 31, 167-172.	0.2	25
105	Predictors of long&#x2013;term clinical response to interferon beta therapy in relapsing multiple sclerosis. <i>Journal of Neurology</i> , 2006, 253, 287-293.	1.8	113
106	The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005, 167, 131-137.	1.1	56
107	Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. <i>Journal of the Neurological Sciences</i> , 2003, 215, 3-8.	0.3	61
108	Proteolytic Balance in Patients with Multiple Sclerosis During Interferon Treatment. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 689-692.	0.5	6

#	ARTICLE	IF	CITATIONS
109	Topiramate Relieves Idiopathic and Symptomatic Trigeminal Neuralgia. <i>Journal of Pain and Symptom Management</i> , 2001, 21, 367-368.	0.6	56
110	Serial gadolinium-DTPA of spinal cord MRI in multiple sclerosis: triple vs. single dose. <i>Magnetic Resonance Imaging</i> , 2000, 18, 1183-1186.	1.0	13
111	Brain atrophy in relapsing-remitting multiple sclerosis: relationship with "black holes", disease duration and clinical disability. <i>Journal of the Neurological Sciences</i> , 2000, 174, 85-91.	0.3	110
112	A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions. <i>Journal of Neurology</i> , 1999, 246, 97-106.	1.8	9
113	Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon $\beta$ 1a. <i>Journal of Neurology</i> , 1999, 246, 443-448.	1.8	26
114	T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1999, 99, 91-96.	1.1	14
115	Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. <i>Lancet</i> , The, 1999, 353, 964-969.	6.3	476
116	Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. <i>Journal of the Neurological Sciences</i> , 1999, 168, 131-136.	0.3	61
117	Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 1999, 171, 130-134.	0.3	15
118	Quantitative magnetic resonance analysis in vascular dementia. <i>Journal of Neurology</i> , 1997, 244, 246-251.	1.8	26
119	No increase of serum autoantibodies during therapy with recombinant human interferon- $\beta$ 1a in relapsing-remitting multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 1997, 96, 372-374.	1.0	36
120	Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: Relationship to clinical parameters. <i>Journal of Magnetic Resonance Imaging</i> , 1996, 6, 580-584.	1.9	50
121	Bridging Therapies With Injectable Immunomodulatory Drugs in the Management of Multiple Sclerosis: A Delphi Survey of an Italian Expert Panel of Neurologists. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	1